iMDx to Welcome Industry Veteran as Vice President of Medical Affairs to Prepare for Commercial Transplant Assay Launch

• Dr. Nick Ioannou brings decades of academia, industry, and clinical experience in organ transplant, nephrology, cardiology, genetics, and oncology

NASHVILLE, Tenn., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), or iMDx, today announced that it has appointed Dr. Nick Ioannou, M.D., MHA, to the position of Vice President, Medical Affairs.

Dr. Ioannou is a physician-scientist with more than three decades of highly relevant experience spanning clinical practice, diagnostics, regulatory affairs, medical education, and medical affairs. His background includes over fifteen years of field-based collaboration with key opinion leaders across multiple therapeutic areas, particularly in organ transplantation, nephrology, cardiology, pulmonology, genetics, and oncology.

He previously served Guardant Health as a senior staff medical science liaison and field director. Dr. Ioannou has also served in several other senior medical affairs positions, including as a medical science liaison for organ health and genetics at Natera, as director of medical education and medical communications at LA Ort Institute, as director of medical affairs at L-Nutra, and as international medical science liaison for heart and kidney transplant at CSL Behring. He has also held roles at Fresenius, Baxter, and Northwestern University, among others.

Dr. Ioannou’s experience as a medical director and partner in private clinics for nearly 10 years has given him a keen ability to connect with patients and their families, as well as with physicians, nurses, and other healthcare partners, thus building strong and long-lasting professional relationships.

“Dr. Ioannou is a perfect fit for iMDx at this pivotal time given his medical advisory experience in organ transplant, nephrology, cardiology, oncology and genetics. He is a proven leader who is comfortable in academia, industry, and clinical settings,” said iMDx CEO Josh Riggs. “Additionally, he serves as a leader within his broad network of constituents, ranging from academia to industry. We are looking forward to having his expertise and acumen to relate and interact with patients, fellow physicians, and other members of the healthcare system that are key to our success as we launch our first commercial products.”

“I am thrilled to join the leadership team at iMDx, which is innovating at a rapid pace and poised to become a leader in transplant rejection testing,” Dr. Ioannou said. “I believe the market wants a better transplant rejection testing paradigm. I look forward to helping deliver diagnostics that are valuable for our hospital colleagues and their patients.”

Dr. Ioannou received a Bachelor of Science in Microbiology from California State University, Northridge, a Master of Healthcare Administration from Saint Joseph's College of Maine and completed his Medical Doctorate clinical training at Michael Reese Hospital in Chicago.

About Insight Molecular Diagnostics, Inc.

Insight Molecular Diagnostics is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. Investors may visit for more information.

GraftAssureCore™, GraftAssureIQ™, GraftAssureDx™, VitaGraft™, GraftAssure™, DetermaIO™, and DetermaCNI™ are trademarks of Insight Molecular Diagnostics Inc.

Forward-Looking Statements

Any statements that are not historical fact (including, but not limited to, statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” “may,” and similar expressions) are forward-looking statements. These statements include those pertaining to, among other things, the appointment of Dr. Loannou to the position of Vice President, Medical Affairs and his expected contributions to iMDx, and other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of diagnostic tests or products, uncertainty in the results of clinical trials or regulatory approvals, the capacity of Insight Molecular Diagnostics’ third-party supplied blood sample analytic system to provide consistent and precise analytic results on a commercial scale, potential interruptions to supply chains, the need and ability to obtain future capital, maintenance of intellectual property rights in all applicable jurisdictions, obligations to third parties with respect to licensed or acquired technology and products, the need to obtain third party reimbursement for patients’ use of any diagnostic tests Insight Molecular Diagnostics or its subsidiaries commercialize in applicable jurisdictions, and risks inherent in strategic transactions such as the potential failure to realize anticipated benefits, legal, regulatory or political changes in the applicable jurisdictions, accounting and quality controls, potential greater than estimated allocations of resources to develop and commercialize technologies, or potential failure to maintain any laboratory accreditation or certification. Actual results may differ materially from the results anticipated in these forward-looking statements and accordingly such statements should be evaluated together with the many uncertainties that affect the business of Insight Molecular Diagnostics, particularly those mentioned in the “Risk Factors” and other cautionary statements found in Insight Molecular Diagnostics’ Securities and Exchange Commission (SEC) filings, which are available from the SEC’s website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Insight Molecular Diagnostics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Investor Contact:

Doug Farrell

LifeSci Advisors LLC